First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said
You may also be interested in...
CSL Reports Profits Up 63 Percent for FY 2009; Swine Flu Data Expected Next Month
PERTH, Australia - Melbourne-headquartered CSL reported this week that it posted AU$1.15 billion ($943 million) in net profits for FY2009, up 63 percent year on year. With cash flow from operations of AU$1.03 billion, the company is well positioned for an alternative acquisition target after scuttling its $3.1 billion merger with U.S.-based Talecris
CSL Reports Profits Up 63 Percent for FY 2009; Swine Flu Data Expected Next Month
PERTH, Australia - Melbourne-headquartered CSL reported this week that it posted AU$1.15 billion ($943 million) in net profits for FY2009, up 63 percent year on year. With cash flow from operations of AU$1.03 billion, the company is well positioned for an alternative acquisition target after scuttling its $3.1 billion merger with U.S.-based Talecris
China's Sinovac, With High-level Government Backing, Could Win Global Race To Market A/H1N1 Vaccine
BEIJING - With the strong support of China's central government and Beijing health authorities, leading vaccine maker Sinovac Biotech could become the first to cross the finish line in the worldwide race to produce a defense to the A/H1N1 pandemic